What we're reading, January 8, 2016: HHS releases report with full Obamacare enrollment information for all 50 states and the District of Columbia; the expansion of the biosimilars in 2016; and promising Ebola treatment found not effective.
The first HHS report during the third open enrollment period of the Affordable Care Act to include data for all 50 states and the District of Columbia revealed that more than 11.3 million people signed up for coverage through the health insurance marketplaces. This includes the 8.6 million in the 38 states using HealthCare.gov and the 2.7 million people in the 13 states using their own marketplaces. Nearly one-fourth of all plan selections were made by individuals between the ages of 18 and 34. The data is for enrollment through December 26, 2015.
In 2016, the expansion of the biosimilar pipeline will be driven by a number of factors, including growing approvals in Europe and the US and expiring patents, according to an article by the senior medical director of Quintiles Asia and published in India’s The Financial Express. The second wave of biosimilars includes biologics with patents expiring between 2015 and 2020, such as the top-selling products Humira, Enbrel, Rituxan/MabThera, Avastin, Herceptin, and Remicade. There are already more than 160 biosimilars in different stages of development for these drugs.
The most promising treatment for patients with Ebola has been found to be not effective, according to a study published in The New England Journal of Medicine. The experimental treatment used blood plasma from Ebola survivors, who had developed antibodies to neutralize the virus, reported The New York Times. However, the small study of 84 patients found that the survival rate was not significantly better than the rate for patients who did not receive blood transfusions.
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More